此次发表的研究是全球首个将PI3Kδ抑制剂林普利塞与HDAC抑制剂西达本胺联合用于CTCL治疗的前瞻性临床试验，这两种药物均为中国自主研发并已上市的口服药物，本研究验证了其在CTCL中的联合使用潜力，为临床治疗提供了新思路。

A new combination treatment may offer a promising option for patients with relapsed or refractory cutaneous T-cell lymphoma ...

In July 2025, Prescient Therapeutics Ltd. announced a phase 2 study to evaluate the efficacy, safety, pharmacokinetics (PK) ...

丽宝新药（Libo Pharma）21日宣布，成功完成8.5亿元募资。该资金将有助于加速大分子蛋白质免疫新药NM-IL-12的开发，该药物目前正准备启动皮肤T细胞淋巴瘤（CTCL）全球第三期临床试验。另外，丽宝新药也规画今年第四 ...

Special Report: Prescient Therapeutics has raised $3m in a placement to sophisticated and professional investors following a ...

The dynamics of the cutaneous T-cell lymphoma market are anticipated to change owing to the improvement in research and development activities, increasing prevalence, and the rising geriatric ...

VCU Massey Comprehensive Cancer Center is the first site in the United States to be activated in a global Phase 2a clinical ...

The safety and preliminary efficacy of BI-1808 monotherapy are currently being evaluated in Part A of the ongoing Phase 2a (NCT04752826) study in patients with T-cell lymphomas, including CTCL.

Prescient Therapeutics has signalled its position as one of the most advanced oncology companies on the ASX, according to ...

In terms of numbers, CTCL affects around 31,000 people in the U.S. and approximately 38,000 people in Europe. For patients, the high unmet need represents a significant burden.

It’s no secret that the rate of cancer both in Australia, and overseas, appears to be increasing – particularly among young people. While part of the story is an increased ability to diagnose cancers ...